Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Screeners that run automatically... and then email you the results! FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Summit Therapeu ADR (SMMT)

Summit Therapeu ADR (SMMT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 765,020
  • Shares Outstanding, K 201,321
  • Annual Sales, $ 1,810 K
  • Annual Income, $ -88,600 K
  • 60-Month Beta -1.05
  • Price/Sales 436.22
  • Price/Cash Flow N/A
  • Price/Book 5.36
Trade SMMT with:

Options Overview Details

View History
  • Implied Volatility 309.91% ( +59.93%)
  • Historical Volatility 167.33%
  • IV Percentile 82%
  • IV Rank 19.85%
  • IV High 1,399.59% on 05/09/22
  • IV Low 40.12% on 11/16/22
  • Put/Call Vol Ratio 4.09
  • Today's Volume 3,580
  • Volume Avg (30-Day) 3,602
  • Put/Call OI Ratio 1.09
  • Today's Open Interest 35,939
  • Open Int (30-Day) 38,383

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.95 +31.53%
on 01/30/23
5.78 -32.87%
on 01/04/23
-0.37 (-8.71%)
since 12/30/22
3-Month
0.66 +487.88%
on 12/02/22
5.78 -32.87%
on 01/04/23
+2.80 (+259.26%)
since 11/02/22
52-Week
0.66 +487.88%
on 12/02/22
5.78 -32.87%
on 01/04/23
+1.56 (+67.24%)
since 02/02/22

Most Recent Stories

More News
Summit Therapeutics Announces Timing for Rights Offering for Up to $500 Million

Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit” or the “Company”) today announced that the Company’s Board of Directors has set the record date for the Company’s previously announced rights...

SMMT : 3.88 (+2.11%)
Summit Therapeutics Closes Deal with Akeso Inc. to In-License Breakthrough Innovative Bispecific Antibody

Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that we have completed the closing of our previously announced definitive agreement with Akeso Inc....

SMMT : 3.88 (+2.11%)
Summit Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that it will participate in and present at the 41 st Annual J.P. Morgan Healthcare Conference on...

SMMT : 3.88 (+2.11%)
Why Summit Therapeutics Shares Soared This Week

The clinical-stage biopharma stock has been rising all year.

SMMT : 3.88 (+2.11%)
Why Summit Therapeutics Stock Is Skyrocketing This Week

The company announced an important licensing deal.

SMMT : 3.88 (+2.11%)
Akeso Inc. Announces Collaboration and License Agreement for Up to US$5 Billion with Summit Therapeutics to Accelerate Global Development and Commercialization of its Breakthrough Bispecific Antibody, Ivonescimab (PD-1/VEGF)

Akeso Inc. to out-license to Summit Therapeutics exclusive rights to ivonescimab (PD-1/VEGF) for the development and commercialization in the United States,...

SMMT : 3.88 (+2.11%)
Should You Follow the Insider Buying in Summit Therapeutics

Shares of the biopharmaceutical company Summit Therapeutics (SMMT) gained over the past few days, driven by significant insider buying. However, as the stock is down more than 55% this year, would it be...

JNJ : 165.54 (+0.38%)
LLY : 330.70 (-3.46%)
NVS : 86.10 (-2.41%)
SMMT : 3.88 (+2.11%)
SUPN : 42.03 (+1.08%)
Why Summit Therapeutics Stock Popped Today

The biotech's recent upward momentum is showing no signs of fading.

SMMT : 3.88 (+2.11%)
Why Summit Therapeutics Stock Is Soaring Today

Investors responded enthusiastically to key insider buying.

SMMT : 3.88 (+2.11%)
Summit Therapeutics Inc Reports Financial Results and Operational Progress for the Second Quarter Ended June 30, 2022

Menlo Park, California, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its...

SMMT : 3.88 (+2.11%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Summit Therapeutics PLC is engaged in the discovery and development of drug to treat the fatal muscle wasting disease Duchenne Muscular Dystrophy and infections caused by the bacteria C. difficile. Summit Therapeutics PLC is headquartered in Abingdon, the United Kingdom.

See More

Key Turning Points

3rd Resistance Point 4.95
2nd Resistance Point 4.63
1st Resistance Point 4.25
Last Price 3.88
1st Support Level 3.55
2nd Support Level 3.23
3rd Support Level 2.85

See More

52-Week High 5.78
Last Price 3.88
Fibonacci 61.8% 3.82
Fibonacci 50% 3.22
Fibonacci 38.2% 2.62
52-Week Low 0.66

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar